Gold prices steady amid Fed rate cut hopes; Trump-Putin talks awaited
REDWOOD CITY, CA—Jeff Cislini, General Counsel at Revolution Medicines, Inc. (NASDAQ:RVMD), recently sold 2,041 shares of the company’s common stock, according to a filing with the Securities and Exchange Commission. The shares were sold on March 20, 2025, at an average price of $38.71, yielding a total transaction value of $79,008. The transaction comes as the company maintains a strong financial position, with InvestingPro data showing the company holds more cash than debt on its balance sheet.
This transaction was executed as part of a 10b5-1 trading plan, which Cislini adopted on March 20, 2024. After the sale, Cislini retains ownership of 57,723 shares, which includes 54,195 restricted stock units. According to InvestingPro analysis, the stock currently trades near its Fair Value, with analysts setting price targets ranging from $59 to $87.
Revolution Medicines, based in Redwood (NYSE:RWT) City, California, is a biotechnology company focused on developing targeted therapies for cancer. With a market capitalization of $7.3 billion and a current ratio of 14.2, the company maintains strong liquidity despite being in its growth phase. For deeper insights into RVMD’s financial health and growth prospects, investors can access the comprehensive Pro Research Report available on InvestingPro, which includes additional exclusive metrics and analyst recommendations.
In other recent news, Revolution Medicines reported a net loss of $194.6 million for the fourth quarter of 2024, an increase from $161.5 million in the same period the previous year. Despite this, the company maintains a robust cash position of $2.3 billion, supported by $823 million from an equity offering. H.C. Wainwright adjusted its price target for Revolution Medicines to $73, maintaining a Buy rating, while Needham reduced its price target to $59, also keeping a Buy rating. Both firms noted that the company’s higher-than-expected research and development expenses contributed to the larger net loss. Revolution Medicines announced plans for two additional registrational trials of its investigational drug, daraxonrasib, targeting pancreatic ductal adenocarcinoma (PDAC). These trials are expected to begin in the second half of 2025. Investors are advised to watch for forthcoming clinical data on zoldonrasib, expected in the second and third quarters of 2025. Revolution Medicines aims to leverage its strong financial position to advance its clinical-stage RAS inhibitors, with a projected net loss for 2025 estimated between $840 million and $900 million.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.